Expect Cons to Outweigh Pros for the New CAP Antibiotic Lefamulin (Xenleta)

October 2019

Lefamulin (Xenleta, zen-LEH-tah) will be the first oral and IV med in a new class of "pleuromutilin" antibiotics.

It's approved for community-acquired pneumonia (CAP) and can be used alone to cover common bugs...Strep pneumo, H. flu, and Mycoplasma.

Lefamulin is not inferior to moxifloxacin for CAP treatment. And lefamulin costs about $200/day for IV...and $280/day for tabs.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote